Wyniki wyszukiwania - Biblioteka Nauki

1

Alteration of secretory IgA in human breast milk and stool samples after the intake of a probiotic - report of 2 cases

100%

Nikolov P. , Baleva M.

Open Medicine

|

2012

|

tom 7

|

nr 1

25-29

EN

Only a few studies reveal immunological changes in breast milk after the intake of probiotic and none focus on secretory IgA (sIgA). The aim our report was to investigate the levels of sIgA in human breast milk and stools before and after 4 weeks of probiotic intake in a patient with ulcerative colitis (UC) and a control. The study included 2 lactating women: 1 with UC and 1 control. Both received daily 3.75 billion viable Lactobacillus bulgaricus for 28 days. SIgA was measured in breast milk and stools before and after the probiotic intake. The concentration of sIgA in breast milk before the probiotic intake in UC was 408.5 vs 137.4 µg/ml in contol. Fecal sIgA in UC was 420 vs 274 µg/ml in control. After 28 days of probiotic intake there was a decrease in breast milk sIgA in UC but an increase in control - 266.7 vs 914 µg/ml respectively. There was an increase in fecal sIgA both in UC and control - 674.4 vs 1033 µg/ml. It is tempting to speculate that the different sIgA secretion towards the probiotic may be a result of an altered mucosal immune response in UC.

2

Diagnostic significance of anti-annexin-A5 antibody determination

80%

Baleva M. , Hristova M. , Nikolov K.

Open Medicine

|

2010

|

tom 5

|

nr 1

6-11

EN

Anti-annexin A5 antibodies are directed against annexin A5 - a phospholipid-binding protein that belongs to the ubiquitous annexin family. These antibodies were first discovered in 1994 by Matsuda et al. in women with recurrent fetal loss or preeclampsia and in patients with systemic lupus erythematosus and positive lupus anticoagulant and/or anticardiolipin antibodies. Since then anti-annexin A5 antibodies have been the focus of research. In addition to their well known prothrombotic and procoagulant activities the authors discuss the involvement of these antibodies in the pathogenesis of antiphospholipid syndrome, recurrent pregnancy loss, systemic lupus erythematosus and other immune and non-immune disorders. Controversial reports are presented and a possible interpretation of the results is given. The authors suggest the significance of anti-annexin A5 antibodies as an additional diagnostic marker and discuss the necessity of more extensive research on their clinical significance.

3

Annexin V antibodies in multiple sclerosis and SLE/APS

80%

Baleva M. , Stoilova D. , Shotekov P. , Nikolov K.

Open Medicine

|

2013

|

tom 8

|

nr 2

225-228

EN

Multiple sclerosis (MS) is an autoimmune disease with unclear etiopathogenesis. Some MS patients have anticardiolipin (ACL), anti-beta-2-glycoprotein-I (B2GPI) and anti-annexin V (AnV) antibodies. These antibodies can also be found in systemic lupus erythematosus with antiphospholipid syndrome (SLE/APS). The aim of our study was to compare the levels of ACL, B2GPI and AnV antibodies in MS and SLE/APS. Materials and methods: We investigated serum levels of IgG and IgM ACL, B2GPI and AnV in 21 MS patients, 30 SLE/APS patients and 30 controls using ELISA. Results: Mean levels of IgM and IgG ACL and B2GPI in MS were comparable with controls and lower than SLE/APS (p<0.05). Mean levels of IgM AnV in MS were higher compared to SLE/APS and controls (p<0.05); mean levels of IgG AnV in MS were higher than normal but similar to SLE/APS (p>0.05). Discussion: The results show that MS with negative “classic” autoantibodies (ACL and B2GPI) and without clinical data for antiphospholipid syndrome may have other positive antiphospholipid antibodies, such as AnV. Larger studies are needed to clarify whether AnV are epiphenomenon of the vascular and organ damage or they play a pathogenic role in the development of MS.

4

Blue toe syndrome as the initial manifestation of ANCA-associated vasculitis

80%

Marinchev L. , Hristova M. , Baleva M. , Kolarov Z.

Open Medicine

|

2013

|

tom 8

|

nr 5

577-579

EN

The blue (or purple) toe syndrome describes the development of a blue or violaceous discoloration in one or more toes in the absence of obvious trauma, serious cold-induced injury or disorders producing generalized cyanosis. The presence of blue toe syndrome requires the clinician to search for primary systemic vasculitides, as well as for malignancy, underlying infection, thrombosis, cardiovascular pathology and other diseases. An accurate diagnosis is critical because many of the causes threaten life or limb, but the patient’s medical history, accompanying non-dermatologic findings on physical examination and the use of discriminatory laboratory tests are usually more important than the nature of the cutaneous abnormalities. We describe the case of a 53-year-old Caucasian male patient presenting with blue toe syndrome as the initial manifestation of ANCA-associated vasculitis.